News | May 23, 2011

Calypso System Enables Accurate Delivery of Radiation Following Prostate Cancer Surgery

Prostate

May 23, 2011—Calypso Medical Technologies Inc., developer of GPS for the Body technology used for the precise tracking of cancerous tumors during radiation therapy, is exhibiting at the American Urological Association Annual Meeting (booth 4337) and will discuss recent clinical findings suggesting that the Calypso System can be used to more precisely deliver radiation in post-prostatectomy patients.
 
In addition, Calypso will provide onsite physician training on the implantation of miniature Beacon electromagnetic transponders, which are the core of the Calypso System, the only commercially available real-time tracking system for radiation therapy shown to improve patient outcomes for prostate cancer. The annual meeting is taking place from May 14-19 at the Walter E. Washington Convention Center in Washington, D.C.
 
In late 2010, the Canadian Journal of Urology published the first study to demonstrate that the use of the Calypso System in conjunction with adjuvant/salvage radiation therapy in the prostatic bed following radical prostatectomy is a safe and efficacious method for treatment targeting. Seventeen patients were implanted with Calypso’s Beacon electromagnetic transponders and treated with intensity-modulated radiation therapy (IMRT) monitored by the Calypso System. Treatment was well tolerated with no significant side effects. Genitourinary toxicity was noted in ten patients and consisted of Grade 1 and 2 frequency and dysuria. Nine of the 17 patients had at least six months of follow up after completion of treatment and all of these patients had undetectable PSA levels.

A May 2010 clinical study published in Urology reported that patients who underwent primary external beam radiation delivery monitored by the Calypso System experienced fewer prostate radiation side effects - including rectal, urinary and sexual dysfunction - than those undergoing conventional radiation therapy.
 
The Calypso System uses GPS for the Body technology to safely guide radiation delivery during prostate cancer treatment. Beacon electromagnetic transponders, smaller than a grain of rice, are permanently placed in a patient’s prostate or prostatic bed. Each transponder emits a unique radio frequency signal to the Calypso System, which then determines the exact location and motion information about the tumor target. Because the tumor can be accurately tracked and monitored, precise targeted radiation can be delivered to the tumor while sparing surrounding healthy tissue and organs. This is critical because any movement by a patient, including internal movement of the tumor, may cause the radiation to miss its intended target and hit adjacent healthy tissue. Calypso’s real-time position information allows physicians to safely deliver the maximum cancer radiation treatments directly to the tumor. The Calypso System, cleared by the U.S. Food and Drug Administration (FDA) for use in radiation therapy for the prostate and post-operative prostatic bed, has been used to treat more than 10,000 people worldwide.

For more information: www.calypsomedical.com
 

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
AI Detects Unsuspected Lung Cancer in Radiology Reports, Augments Clinical Follow-up
News | Artificial Intelligence | May 20, 2019
Digital Reasoning announced results from its automated radiology report analytics research. In a series of experiments...
New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...